Clinical Trials Browser

Phase 1/2 × Esophageal Squamous Cell Carcinoma × Paclitaxel × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT05312372 2026-02-17

S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC

Phase 1/2 Withdrawn

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05342636 2025-12-17

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Phase 1/2 Completed

90 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT02735239 2024-03-22

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Phase 1/2 Completed

73 enrolled 18 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06303583 2024-03-12

CRIS

Phase 1/2 Enrolling by invitation

30 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05394415 2022-05-27

LATE

Phase 1/2 Unknown

30 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03278626 2022-03-28

Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma

Phase 1/2 Terminated

12 enrolled 8 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04506138 2021-12-14

Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma

Phase 1/2 Unknown

46 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT00002984 2012-05-24

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus

Phase 1/2 Completed

26 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Clinical Trials

MK-3475-06B

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

CRIS

LATE

Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma

Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus